QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: How the EU Centralised Marketing Authorisation Procedure Works

Test your understanding of the concepts covered by How the EU Centralised Marketing Authorisation Procedure Works.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which pairing correctly matches a procedural layer with the question it addresses?

Evidence — What legal act gives the conclusion binding effect? Scientific assessment — What information is available? Regulatory conclusion — Does the evidence support the proposed conditions of use and benefit-risk balance? Legal act — What remains uncertain in the underlying data?

Question 2 of 10 What is the regulatory purpose of a clock stop following questions from CHMP?

To suspend all applicant obligations indefinitely To provide a formal period for the applicant to prepare responses while preserving the active-assessment framework To convert the CHMP opinion into a Commission decision To eliminate the need for additional scientific assessment

Question 3 of 10 An application passes validation but later receives substantial questions about efficacy and safety. What does this demonstrate?

Validation is a preliminary scientific approval Validation confirms only that the application is sufficiently compliant and complete for the formal scientific procedure to proceed The later questions indicate that the validation decision was invalid A validated application cannot receive additional questions

Question 4 of 10 Why is an eligibility request particularly important for a product in optional centralised-procedure scope?

It replaces the need for a complete marketing-authorisation dossier It provides a defensible justification that the product satisfies the conditions for using the optional Union route It guarantees a positive CHMP opinion It determines the final wording of the product information

Question 5 of 10 Which document represents the formal scientific conclusion of CHMP rather than a preliminary or supporting assessment?

The rapporteur assessment report The initial eligibility request The adopted CHMP opinion The electronic submission receipt

Question 6 of 10 What is the defining regulatory consequence of a successful EU centralised procedure?

Separate national marketing authorisations are issued by each Member State A single Union marketing authorisation is granted that is valid across the EU and, under the applicable framework, the EEA EMA becomes the legal holder of the marketing authorisation The applicant receives only a scientific recommendation with no authorisation

Question 7 of 10 Which applicant practice is most important when preparing responses to regulatory questions?

Address only the question that appears most likely to affect the opinion Provide a general narrative response and leave cross-dossier updates until after approval Map each question to supporting evidence, explain the reasoning and maintain consistency across the dossier and product information Avoid proposing changes because assessors cannot consider amendments during assessment

Question 8 of 10 Why should the standard 210-day assessment framework not be treated as a fixed 210-calendar-day period from submission to opinion?

The 210 days refer only to the period before submission The framework measures active assessment time and excludes applicable clock stops while the applicant responds The Commission may always extend the period without procedural basis The period includes only time spent on manufacturing inspections

Question 9 of 10 What is the correct interpretation of advice obtained during a pre-submission interaction with EMA?

It constitutes a binding commitment to a positive CHMP opinion It confirms that the submitted dossier will pass validation It helps clarify procedural and regulatory expectations but does not predetermine the scientific outcome It transfers responsibility for dossier preparation from the applicant to EMA

Question 10 of 10 Which statement most accurately distinguishes EMA, CHMP and the European Commission in the centralised procedure?

EMA adopts the legally binding authorisation after CHMP provides administrative support CHMP grants the marketing authorisation and the Commission performs scientific assessment EMA coordinates and supports the process, CHMP adopts the scientific opinion, and the Commission adopts the legally binding decision The European Commission coordinates the scientific assessment while EMA adopts the final opinion

Knowledge Assessment: How the EU Centralised Marketing Authorisation Procedure Works

Cookie Settings